Form 4: Pulse Biosciences Director Acquires 200,000 Stock Options

Director Mahkam Zanganeh acquired 200,000 stock options in Pulse Biosciences, Inc. on August 9, 2024.

Summary

• On August 9, 2024, Mahkam Zanganeh, a director of Pulse Biosciences, Inc. (PLSE), acquired 200,000 stock options.
• The exercise price of these options is $15.65.
• One-fourth of the shares will vest on the date of the Issuer's next annual meeting of stockholders.
• The remaining shares will vest monthly over three years, contingent upon continued service.
• The options expire on August 9, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. While insider ownership can be a positive signal, this event alone doesn't strongly indicate bullishness or bearishness.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the options is tied to the director's continued service, suggesting an expectation of ongoing involvement with the company.

Industry Context

This is a standard SEC Form 4 filing, reporting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into insider transactions.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates